U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07560410) titled 'Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)' on April 24.
Brief Summary: This is an investigator-initiated, single-center clinical trial evaluating the efficacy and safety of ALK inhibitors in patients with locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. Eligible patients must have disease progression after standard therapy or no suitable standard treatment options.
Participants will receive either crizotinib (Xalkori(R)) or alectinib (Alecensa(R)), with treatment selection determined by the study investigators. The study aims to assess an...